Shares of Atara Biotherapeutics ATRA plunged 40.5% on Thursday after the FDA issued a complete response letter (CRL) against the company’s biologics license application (BLA) seeking approval of lead ...

Jan 16 (Reuters) - The U.S. Food and Drug Administration on Thursday declined to approve Atara Biotherapeutics' (ATRA.O), opens new tab therapy to treat patients with a rare cancer that develops ...

Atara Biotherapeutics (NASDAQ:ATRA) has announced plans to cut around 50% of its workforce, just a little over a week after it said the FDA had declined to approve its immunotherapy Ebvallo.

Atara Biotherapeutics ATRA is a nimble allogeneic T cell immunotherapy ... EBV+ PTLD is a rare hematologic malignancy (blood cancer) with a high mortality rate and occurs after patients undergo ...

Atara Biotherapeutics, Inc.’s ATRA share price has surged by 12.53%, which has investors questioning if this is right time to ...

Atara Biotherapeutics has just announced a CRL by FDA for EBVALLO. Click here to read more about ATRA stock and why it is rated as a Buy.

H.C. Wainwright analyst Robert Burns has reiterated their neutral stance on ATRA stock, giving a Hold rating on January 21.Invest with ...